Our Products

ViruCure is developing a novel biological pharmaceutical platform (NADAV) for targeted treatment of diverse cancers.

Glioblastoma Multiforme (GBM)

GBM is one of the most aggressive cancers that begins within the brain.  Though it is rare, with an incidence of 2–3 cases per 100,000 in Europe and North America, it has one of the highest mortality rates.

The current prognosis is very poor.

  • Using current standard of care treatment, the median survival from diagnosis is 14.6 months and only 30% of patients survive after two-years.
  • Even after “total resection” of an obvious tumor more than 90% of patients develop recurrent tumors that are resistant to radiation and chemotherapy treatment.
We aim to leverage the promising safety and efficacy results from this initial clinical trial to bring rapidly to market through US and EU Orphan Drug designations a breakthrough treatment for this deadly disease.

Lung cancer (LC)

Lung Cancer is the leading cause of cancer death worldwide. In 2017, there was approximately 240,000 new lung cancer (LC) cases diagnosed in the United States and it was the cause of over 150,000 deaths”

There are currently very few effective therapeutic options.  We will leverage pre-clinical studies on our NADAV platform that show an oncolytic effect on primary and metastatic LC.

Promising clinical Results